Asked about the Innova application, Shuren, the FDA official, responded broadly, emphasizing the need for solid data. "We consider tests for at-home use to be a top priority,” he said. “And if they've got their data and the data looks good, we authorize."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.